FDA seeks public input on controversial priority voucher scheme amid concerns about its transparency and legality.

Apogee Therapeutics said its moderate-to-severe eczema candidate could offer much more convenient dosing over standard treatments based on its latest mid-stage results. Monday’s Phase 2

Insmed’s Phase 3 trial win for Arikayce in a particular kind of lung infection sets up the drug to expand into the front-line setting —

Sanofi is back in the T cell engager business after a couple years of fluctuating interest, extending its support to a relatively unknown California startup

Dizal’s Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of